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AbstrAct
Introduction Adolescents and young adults (AYA) with 
cancer require dedicated clinical management and care. 
Little is known about the training and practice of European 
healthcare providers in regard to AYA and the availability of 
specialised services.
Methods A link to an online survey was sent to members 
of the European Society for Medical Oncology (ESMO) and 
the European Society for Paediatric Oncology (SIOPE). 
The link was also sent to ESMO National Representatives 
and circulated to other European oncology groups. 
Questions covered the demographics and clinical training 
of respondents, their definition of AYA, education about AYA 
cancer, access to specialised clinical and supportive care, 
research and further education. Data from Europe were 
analysed by region.
Results Three hundred tweenty two questionnaires 
were submitted and we focused on data from the 266 
European healthcare professionals. Responses revealed 
considerable variation both within and between countries 
in the definition of AYA. Over two-thirds of respondents 
did not have access to specialised centres for AYA (67%), 
were not aware of research initiatives focusing on AYA with 
cancer (69%) and had no access to specialist services 
for managing the late effects of treatment (67%). The 
majority of the respondents were able to refer AYA patients 
to professional psychological support and specialised 
social workers. However, more than half had no access 
to an age-specialised nurse or specialised AYA education. 
Overall, 38% of respondents reported that their AYA 
patients did not have access to fertility specialists. This 
figure was 76% in Eastern Europe. Lack of specialised AYA 
care was particularly evident in Eastern and South-Eastern 
Europe.
Conclusion There is important underprovision and 
inequity of AYA cancer care across Europe. Improving 
education and research focused on AYA cancer care should 
be a priority.
IntRoduCtIon
Adolescents and young adults (AYA) are a 
distinct group at the interface between chil-
dren’s and adult’s cancer services. Although 
the definition of AYA differs from country 
to country, a recent authoritative review of 
cancer epidemiology adopts the age limits 
of 15–39 years.1 In 2014, 31% of the popu-
lation of Europe was aged between 15 and 
39. Numbers were relatively evenly spread 
throughout this range, with 5%–7% of the 
population falling within each quintile.
Cancer in the AYA population is 
uncommon,2%–4% of all invasive malignan-
cies overall depending on precise definitions. 
However, the annual incidence of cancer 
in the 15–39 years age group is significant 
and estimated to be 50–70 000 in Europe2 
and 1 million worldwide.3 The incidence of 
cancer increases with age, from childhood 
to adulthood; between the ages of 15 and 30, 
cancer is 2.7 times more frequent than in the 
under 15 age group.4 More worrisome is the 
observation that the incidence of AYA cancer 
is rising for both males and females and in all 
age quintiles between 15 and 39 years.5 The 
distribution of cancer types among AYA differs 
from that in both older and younger people. 
The peak incidence of Hodgkin’s lymphoma, 
germ cell tumours and bone sarcomas occurs 
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Key questions
What is already known about this subject?
 ► Little is known about the training, practice and needs 
of European healthcare providers in relation to care 
of adolescents and young adults (AYA) with cancer.
What does this study add?
 ► This survey revealed important underprovision and 
inequity of specialised  AYA cancer care across 
Europe. This was particularly evident in Eastern and 
South-Eastern Europe.
How might this impact on clinical practice?
 ► AYA with cancer require particular clinical 
management and care in relation to fertility 
preservation and other treatment sequelae. 
Improving care through education and research 
focused on AYA should be a priority for both European 
Society for Medical Oncology and European  Society 
for Paediatric Oncology.
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within the AYA range. Among 15–39-year-olds as a whole, 
the most frequent diagnoses are breast carcinoma (18% 
of cases), melanoma (14%), germ cell tumours (13%), 
carcinomas of the female genital tract (11%), thyroid 
cancer (7%) and Hodgkin and non-Hodgkin lymphomas 
(7% and 5%, respectively).1
Survival rates for AYA have not improved to the extent 
that they have for younger children or older adult cancer 
populations,1 6 but recent data have shown that the gap 
is reducing.2 Poorer outcomes in AYA (particularly those 
with colon or breast cancer) may be in part related to their 
biology, including different genomic risk, tumour histo-
pathology, oncogenic pathway activation and sensitivity 
to chemotherapy.7 In addition, AYA patients tend to be 
diagnosed at later stages compared with older patients.8 9
Increasing numbers of AYA are long-term cancer survi-
vors, given the high survival rate for AYA with cancer, and 
the fact that younger patients have low mortality from 
other diseases. Therefore, several issues arise in this group 
and include the effects of the disease and its treatment 
on fertility, cognitive function and mental health, and 
the risks of late-occurring adverse events such as cardio-
toxicity, nephrotoxicity and second primary tumours.10 11 
The specific circumstances and needs of AYA survivors 
are now being increasingly recognised and, internation-
ally, various recent priorities have been set in this field. In 
the USA in 2013, an update meeting was held to review 
evidence, scientific data and priorities for individuals 
aged 15–39 at cancer diagnosis.12 A group of 60 experts 
identified the large increase in published research in 7 
years, and prioritised next steps.
In 2016, the European Society for Medical Oncology 
(ESMO) and the European Society for Paediatric 
Oncology (SIOPE) recognised these issues and created 
a joint working group on Cancer in Adolescents and 
Young Adults. Its aims are to provide educational content 
to members interested in care of AYA with cancer, to 
increase wider professional awareness of the needs of 
AYAs with cancer and to cultivate sensitive collaborative 
relations between medical and paediatric oncologists as 
well as with other healthcare professionals involved in AYA 
cancer care. The results from an online survey reported 
here is among the first fruits of this collaboration in the 
effort to record the current situation of AYA cancer care 
in Europe. Our objectives were to record the current situ-
ation in AYA cancer care in Europe, to ensure the ESMO 
and SIOPE Joint Working Group provides educational 
content on AYA issues that is of interest to members of 
both societies, and finally to increase professional aware-
ness of AYA cancer related issues.
MetHods
The ESMO/SIOPE Working Group conducted an online 
survey in the last quarter of 2016. The questionnaire aimed 
to obtain data on the availability of the services special-
ised to AYA cancer care and clinical management, cancer 
risk assessment and gentic counseling management, 
educational activities available to healthcare providers 
interested in the AYA field, efforts to maintain the health 
of AYAs living after cancer and means of raising aware-
ness and improving care and outcome. The demographic 
characteristics of the responders as well as their views on 
the age range that should be considered ‘AYA’ were also 
recorded.
The survey was freely available on the open-access 
ESMO website (to which the SIOPE site was linked) and 
a link sent by email to all members of ESMO and SIOPE. 
The link was also sent to ESMO National Representatives 
in each European country, so that it could be promoted 
nationally, and to several European oncology groups. It 
was also promoted at several conferences, such as the 
48th Annual Congress of the International Society of 
Paediatric Oncology and the 1st Global Conference on 
Cancer in Adolescents and Young Adults. The survey was 
therefore not confined exclusively to people who had a 
known interest in AYA patients with cancer.
Data from Europe were analysed by region using χ2 
and Fisher’s exact test. Analyses were performed using 
the statistical software R. European regions were defined 
according to the WHO geographical distribution.13
Results
Characteristics of respondents
From the outset, the survey was intended primarily as a way 
of obtaining information on the current situation in Europe 
relating to the care of AYA patients. However, the online 
availability of the questionnaire meant that responses were 
also spontaneously obtained from a small number of clini-
cians outside Europe (n=56) who were excluded from 
this analysis. There were 266 respondents from Europe, 
55% women and 45% men (figure 1). The age distribu-
tion was as follows: 20–29 years, 11%; 30–39 years, 29%; 
40–49 years, 26%; 50–59 years, 25%; 60 years or more, 
9%. Almost half (48%) were medical oncologists and 21% 
paediatric oncologists. Eight per cent were in training, 5% 
were haematologists, 4% were radiation oncologists and 
2% were surgical oncologists. The remainder were spread 
through other professional roles such as oncology nursing.
The majority of respondents (52%) worked in general 
academic centres, with 19% in specialised cancer hospi-
tals and 11% in paediatric hospitals. Sixty per cent had 
been trained to treat adult patients with cancer, 25% to 
treat paediatric cases and 15% both. There were wide 
differences in the number of patients aged 15–39 years 
that they had treated over the past year: Thirty-two 
per cent had treated between 1 and 10 such patients, 28% 
had treated 11–20, 17% had treated between 21 and 50 
cases and 16% had more than 50. Given that patients aged 
15 to 39 represent only 2% of the total cancer population, 
these data suggest that our respondents were predomi-
nantly those with a particular interest in the AYA cancer 
field. Twenty-four participants (9%) provided no further 
information. Data for the remaining questions are there-
fore based on 242 respondents.
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Figure 1 European survey respondents by region. Region respondents, n (%): Eastern Europe 35 (13.2), Northern Europe 
49 (18.4), Southern Europe 85 (32.0), Western Europe 97 (36.6), TT 266 (100). Eastern Europe: Belarus (n=2), Bulgaria (n=2), 
Czech Republic (n=3), Georgia (n=1), Hungary (n=3), Poland (n=5), Romania (n=8), Russia (n=5), Slovakia (n=3), Ukraine (n=3). 
Northern Europe: Denmark (n=5), Estonia (n=2), Finland (n=1), Iceland (n=1), Ireland (n=5), Latvia (n=2), Lithuania (n=4), Norway 
(n=1), Sweden (n=4), UK (n=24). Southern Europe: Albania (n=2), Andorra (n=1), Bosnia and Herzegovina (n=1), Croatia (n=6), 
Cyprus (n=3), Greece (n=27), Italy (n=15), Malta (n=2), Montenegro (n=1), Portugal (n=11), Serbia (n=3), Slovenia (n=2), Spain 
(n=9), (Former Yugoslavic Republic of) Macedonia (n=2). Western Europe: Austria (n=2), Belgium (n=13), France (n=26), 
Germany (n=37), Luxembourg (n=1), Netherlands (n=9), Switzerland (n=9). 
Figure 2 Awareness of respondents about the availability or development of specialised services for AYA where adult and 
paediatric cancer specialists work together to plan treatment and deliver care.
Age range considered as AYA, management and clinical 
outcome
There was considerable variation both within and 
between countries in the age range considered as 
covered by the term ‘AYA’. In Belgium, for example, 
the ages thought appropriate to define the lower limit 
varied from 10 to 16 years, and the upper limit ranged 
from 24 to 35 years. In the case of Germany, the lower 
limit ranged from 10 to 18 years and the upper limit 
from 22 to 39 years. Overall, there was little consistency 
in defining the lowest age thought to define the start of 
the AYA group, but some consistency in seeing its upper 
limit as lying between 35 and 39 years.
Respondents were presented with three hypothetical 
patients—all aged 17 years—and asked whether (in their 
country) the doctor leading patient management would 
have been trained in adult or paediatric oncology. In 
the case of a patient with metastatic soft tissue sarcoma, 
56% of respondents said that the lead clinician would 
have been paediatrics trained. This figure rose to 71% 
when the patient had acute lymphoblastic leukaemia, 
but fell to 44% when the patient had metastatic embry-
onal carcinoma of the testis.
When asked if their patients could access to special-
ised services for AYA with cancer, or if such services 
were in development, 67% of respondents overall said 
they could not. This figure rose to 87% in Eastern 
and South-Eastern Europe. For Western Europe, the 
figure was 55%. In contrast, only 40% of respondents 
from Northern Europe said they did not have access 
to specialist services for AYA patients with cancer 
(figure 2).
There was also a significant difference in knowl-
edge about having access to such services according 
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Table 1 Access of AYA patients to professional supportive care, by European region
Type of accessible support specialist (%)
Eastern 
Europe
Northern 
Europe Southern Europe Western Europe
No Yes No Yes No Yes No Yes p Value
Professional psychological support 26 74 19 81 17 82 3 97 0.0011
Social worker 48 52 9 91 34 66 9 91 <0.001
Physiotherapist/occupational therapist 29 71 23 77 35 65 14 86 0.0108
Education or training mentor 68 32 67 33 76 24 50 50 0.0041
Age-specific specialist nursing 68 32 49 51 90 10 47 53 <0.001
Support group with other young people 52 48 19 81 66 34 40 60 <0.001
to the specialty of respondent: 62% of haematolo-
gists reported to have access to AYA services, 44% of 
paediatric oncologists but only 27% of medical oncol-
ogists (p=0.007 for interaction according to specialty). 
Hospital type and number of patients treated did not 
significantly influence perceived access to specialised 
services (p=0.50 and 0.15, respectively).
When asked whether they were aware of how trends in 
outcome for AYA with cancer compared with those for 
children or older adults, 62% said they were not.
Alarmingly, more than two-thirds of respondents were 
not aware of research initiatives, clinical trials or studies 
(near them or further afield) focused on the specific 
clinical, epidemiological or psychosocial features of 
AYA with cancer. This figure was highest among respon-
dents from Eastern and Southern Europe (90% and 
88%, respectively) and lowest (46%) among those from 
Northern Europe (test for interaction according to 
region, p<0.001). There were also major differences 
between specialties (p<0.001), with haematologists 
being the most likely (62%) to be aware of relevant clin-
ical trials or studies, while this was true for only 38% of 
paediatric oncologists and 23% of medical oncologists.
sources of support for AYA patients
Eighty-six per cent of respondents said their AYA patients 
had access to professional psychological support. In 
total, 78% of respondents said their AYA patients 
had access to a social worker and 76% had access to 
a physiotherapist or occupational therapist (PT/OT). 
In relation to services of particular relevance to young 
people, 54% of respondents said their AYA patients had 
access to a support group with other young people, 36% 
had access to an education or training mentor and 36% 
had access to age-specific specialist nurse.
Access to supporting specialists was significantly 
different across European regions but (as detailed in 
table 1) regional differences varied depending on the 
nature of the support. At least 50% of respondents 
across all four European regions reported that profes-
sional psychological support and access to social workers 
and PT/PO were available to AYA patients. According 
to respondents, education or training mentors were not 
generally available in Eastern, Northern and Southern 
Europe, and they were available in only 50% of cases 
in Western Europe. In Eastern and Southern Europe, 
access to an age-specific specialist nurse and a support 
group with other young people is available in fewer 
than 50% of cases, but the majority of AYA patients in 
Northern and Western Europe have such access. Social 
workers and age-specific nursing availability was signifi-
cantly related to specialty, and access to PT/OTs and 
mentors varied by type of hospital. Access to a support 
group of other young people was significantly related to 
the number of patients treated by the respondent.
long-term consequences of treatment and disease prevention
Sixty-two per cent of respondents said that their insti-
tution provided AYA patients with access to a fertility 
specialist who could be consulted in relation to their 
wishes about having children after cancer therapy. 
This figure was highest in Northern Europe (72%) and 
lowest in Eastern Europe (24%), representing a signif-
icant discrepancy across the four European regions 
(figure 3; p<0.001).
Ninety-one per cent reported that patients who had 
had potentially cardiotoxic treatment were evaluated for 
modifiable cardiovascular risk factors such as high blood 
pressure, high cholesterol and obesity. Similar propor-
tions of patients were advised on the importance of a 
healthy approach to maintain normal body weight, limit 
alcohol consumption, adopt a healthy diet, increase phys-
ical activity and enjoy the sun safely.
Sixty-nine per cent of respondents said they asked 
patients about their smoking habits at every visit, and 
96% advised smokers to quit. Sixty-six per cent suggested 
referral to a smoking cessation service.
In relation to vaccination, only 6% of respondents 
said that they reviewed the vaccination status of all AYA 
patients at every visit, while 25% reviewed it annually 
and 50% occasionally. Seventy-eight per cent advocated 
human papilloma virus (HPV) vaccination for female 
patients aged 9–26 years, but only 20% advocated this for 
male patients in the same age range. This may reflect the 
fact that in many countries, HPV vaccination of boys is 
not part of the cancer prevention strategy.
Only one-third of respondents overall (33%) had 
access to a specialist service to which they could refer 
patients some years after completion of cancer treat-
ment. This service was envisaged as providing education 
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Table 2 Prioritisation of respondents’ interests in 
educational activities that the European Society for Medical 
Oncology and the European Society for Paediatric Oncology 
could offer together
1 (top 
priority) 2 3
4 (least 
priority)
Cancer treatment 
services and their quality 
improvement for AYA (%)
53 19 17 11
Survivorship health for AYA 
after cancer (%)
35 27 20 18
Cancer risk assessment 
and cancer prevention in 
AYA (%)
31 27 23 19
Basic science and clinical 
research about AYA 
cancer (%)
30 33 21 16
AYA, adolescents and young adults.
Figure 3 Availability of a fertility specialist providing consultation to adolescents and young adults willing to have children 
after their cancer treatment at respondent’s institution.
and minimising the risk of late effects or enhancing 
their management. Even in Northern Europe, only 47% 
of respondents reported that they had access to such a 
service.
Family history
Seventy-one per cent of respondents overall said they felt 
competent in using a family history to screen AYA patients 
for the more frequent hereditary syndromes that predis-
pose to young-onset cancer. In addition, 89% had access 
to a genetic service for AYA patients with a family history 
that suggested a hereditary cancer syndrome. Among 
respondents in Northern and Western Europe, this figure 
was as high as 95%, falling slightly but not significantly to 
83% and 81% in respondents from Eastern and Southern 
Europe, respectively.
Improving the service
Forty-four per cent of respondents said that their unit, 
hospital, region or country asked AYA patients about the 
quality of their care as part of an effort to improve services, 
but only 18% of healthcare professionals reported having 
access to education and training courses (online or face-
to-face) that were focused on the management of AYA 
with cancer. Haematologists (31%) and paediatric oncol-
ogists (27%) were more likely to have such access, as were 
health professionals seeing more than 50 AYA patients per 
annum. In Northern Europe, this figure was only 39%.
When asked to rank their interest in educational activ-
ities that ESMO and SIOPE might jointly undertake, 
53% gave their highest priority to activities that will assist 
them to improve cancer treatment for AYA. Survivorship 
issues for AYA after cancer, cancer risk assessment and 
prevention and basic science and clinical research into 
AYA with cancer received lower rankings overall, with 
top priority being assigned by similar proportions (30%–
35%) of respondents (table 2).
dIsCussIon
Cancer in AYA represents a unique disease constellation 
with distinct epidemiological, clinical and biological 
characteristics that resemble neither to childhood 
cancer nor cancer in older adults.1 2 5 7 The lower inci-
dence of AYA-onset cancer, along with the paucity of 
data from cancer clinical trials in this age group, limit 
substantially our knowledge on this group of patients 
with cancer. In the present study, we tried to record the 
current status of AYA cancer care across Europe and to 
identify potential gaps in education, clinical services 
and psychosocial support availability for these patients. 
We found that over two-thirds of respondents did not 
have access to specialised centres for AYA (67%), were 
not aware of research initiatives focusing on AYA with 
cancer (69%) and had no access to specialist services 
for managing the late effects of treatment (67%). We 
also identified alarming rates of lack of specialised 
supporting services, with more than half of respondents 
reporting that they had no access to an age-specialised 
nurse or specialised AYA education, and 38% reported 
that their AYA patients did not have access to fertility 
specialists. This lack of services was particularly evident 
in Eastern and South-Eastern Europe.
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Regarding age range considered as AYA, the data 
obtained from this survey broadly agree with those of 
Desandes and Stark who report AYA services in France 
and the UK as being directed at patients aged 15–24/25 
years,1 while in Spain, the figures were 14–30 years, and 
in the Netherlands, 18–35 years.14 Similar variation in 
the definition of the patient age range has been docu-
mented in the e-Delphi survey, in which 75% agreement 
on a single definition of the patient age range within 
AYA cancer care has been reached.15 Since the optimal 
AYA age range remains an elusive topic on which to 
agree, we believe that treating physicians should treat 
according to the needs of the community they serve, 
ensuring that those who fall in the interface between 
children and adult service have their needs met.14
Our survey uncovered the lack of access of the 
responders to centres that specialise to treat AYA with 
cancer. The need for specific services for this popula-
tion of patients has been appreciated in the replies to 
a recent questionnaire for AYA with cancer that has 
been designed by AYA oncology specialists in the UK 
and translated into 11 other European languages.16 
Two-thirds of the 301 participants from 25 countries 
agreed with the need for AYA-specific services. Partic-
ipants reported that important aspects of teenage and 
adolescents care included access to psychological care, 
youth workers and physiotherapists, higher levels of 
staffing and healthcare workers who understand the 
needs of this population and communicate effectively. 
Given the importance of psychosocial issues in AYA, it 
is comforting to identify that the majority of respon-
dents were able to refer AYA patients to professional 
psychological support and specialised social workers. 
However, more than half had no access to an age-spe-
cialised nurse, specialised AYA education or a learning 
mentor, which is extremely important for these patients 
who feel that they lag behind in their education. More-
over, 38% of respondents said their AYA patients did 
not have access to fertility specialists. This figure rose to 
76% in Eastern Europe. Given the youth of the popula-
tion being treated, the latter findings are perhaps the 
most disturbing and identify a gap where future efforts 
from both societies should be concentrated.
Teenage and young adults with cancer have endorsed 
‘monitoring after treatment’, ‘communication between 
professionals and young people’, ‘research about 
cancer’, ‘fertility preservation’ and ‘back to work/
school’ as areas of priorities for future research.16 
There is, therefore, an agreement with the interests 
of the responders to our survey about the educational 
activities that ESMO and SIOPE should offer together. 
In our ESMO and SIOPE joint Working Group, we are 
currently elaborating on how to increase professional 
awareness on AYA cancer issues to provide adequate 
educational material by means of E-learning, devel-
oping guidelines, practical guides for clinicians and 
congress activities such as educational lectures and 
interactive sessions focusing on AYA.
Intriguingly, there were certain marked differences 
between respondents in different branches of cancer 
medicine. Haematologists included in this survey were 
more likely than medical or paediatric oncologists to 
have patients who could access specialist services for 
AYA patients, and more aware of research involving the 
specific situation of AYAs with cancer. The proportion of 
respondents whose patients had access to fertility special-
ists was lowest among medical oncologists (54%), similar 
for radiation oncologists and haematologists (67% and 
69%) and highest among paediatric oncologists (75%). 
Paediatric oncologists were also the most likely (46% vs 
an overall figure of 33%) to have access to a service that 
aimed to minimise and manage the late effects of cancer 
treatment. These findings may reflect the more special-
ised and multidisciplinary care of paediatric patients with 
cancer as compared with adults, given the fact that many 
paediatric cancer centres are more likely to offer a large 
number of support services, including psychologists, 
social workers, fertility specialists and access to cancer 
clinical trials.
Among the strengths of the current work are the inter-
national profile of respondents that covers all areas of 
Europe, and the representative nature of our sample 
that includes all professional disciplines that provide care 
to AYA with cancer, rendering our results reliable for ‘real 
world’ clinical practice. Notably, the questionnaire was 
available jointly by both ESMO and SIOPE, providing thus 
the opportunity for equal distribution of respondents. 
However, it should be noted that an inevitable selection 
bias should have occurred, given the fact that healthcare 
professionals with a special interest in AYA were more 
likely to undertake the questionnaire as compared with 
general specialists. In addition, as shown in figure 1, the 
number of responses was not equally distributed across 
European countries, with countries known to have more 
developed AYA services being more likely to have a 
higher number of responses, which may have introduced 
an additional bias.
Inclusion in the analysis of data from the 56 respon-
dents who practised outside Europe at this stage would 
not be informative at statistical level, but probably 
makes little substantive difference to conclusions about 
underprovision of AYA cancer-specific services. Egypt 
(six respondents), India (four respondents) and Brazil 
(three respondents) were the countries that were most 
frequently represented. The remaining respondents 
were widely spread across countries of the USA, Africa, 
Middle East and Asia. Numbers were too few to allow 
subdivision by global region. However, the willing-
ness of clinicians from outside Europe to respond to a 
survey focused on Europe shows global interest in issues 
relating to the better management of AYA patients with 
cancer. We plan to collaborate with colleagues from 
overseas and map the AYA care and needs in other 
continents.
This survey, while not definitive, is a helpful starting 
point. It suggests the need to expand awareness of the 
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particular needs of AYA patients with cancer among 
health professionals and to encourage provision of 
specialist services that will improve their lives after 
cancer. There is considerable opportunity for ESMO 
and SIOPE to work together in raising the profile of AYA 
cancer-related issues, in providing educational mate-
rials (perhaps focused initially on those who express a 
particular interest in AYA patients) and in encouraging 
research.
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